Mataro

• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• Avelumab Program Rollover Study Ended recruitment
  2024-514274-46-00 5 2019-06-21 Solid Tumors
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk … Ended recruitment
  2023-505223-31-00 4 2019-06-14 Localized ER+ breast cancer
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended
  2022-503071-28-00 5 2023-08-31 Squamous Non-small cell Lung Cancer
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• Evaluation of the efficacy and safety of topical treatment on clinical signs and symptoms of dry eye disease associated with moderate meibom … Ended
  2024-518093-13-00 6 2021-10-26 Dry Eye and Meibomian Gland Dysfunction
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr … Ended
  2024-514611-98-00 5 2021-07-20 PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previousl
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer

Showing 25–33 of 33 trials